CJC-1295 No DAC

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

CJC-1295 No DAC — GHRH Analog / Pulsatile Growth Hormone Secretagogue

CJC-1295 No DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a synthetic 30-amino acid analog of endogenous growth hormone-releasing hormone (GHRH). Developed as a structurally stabilized version of the naturally occurring GHRH(1-29) fragment, CJC-1295 No DAC incorporates strategic amino acid substitutions that confer resistance to enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4), significantly extending its active window compared to native GHRH while preserving its physiologically pulsatile release pattern. The absence of the Drug Affinity Complex (DAC) — which in the DAC variant enables covalent albumin binding and a half-life of ~8 days — is the defining pharmacokinetic feature of this form, giving it a half-life of approximately 30 minutes and making it the preferred variant for research into pulsatile GH axis dynamics.

Why the No DAC Form Matters in Research

The distinction between the DAC and No DAC variants is not merely a matter of dosing convenience — it represents two fundamentally different pharmacodynamic profiles with different research implications. CJC-1295 No DAC mimics the body’s natural GHRH pulse architecture, triggering discrete, physiologically patterned GH release events from anterior pituitary somatotrophs. The DAC form, by contrast, produces sustained, non-pulsatile GH elevation — a profile that is useful for certain endpoints but conflates the effect of continuous stimulation with the effect of physiological pulsing. For researchers studying GH axis regulation, receptor dynamics, or the downstream consequences of pulsatile vs. sustained secretion, the No DAC form provides the more controlled and physiologically relevant signal.

CJC-1295 No DAC is frequently studied in combination with GH secretagogues such as Ipamorelin, which act on a separate receptor (GHS-R1a) and synergize with GHRH signaling to amplify GH pulse amplitude without sacrificing pulsatility.

Research Applications

CJC-1295 No DAC is used in studies examining:

• Pulsatile GH secretion dynamics and somatotroph receptor responsiveness
• GH/IGF-1 axis characterization in dose-response and timing protocols
• Comparative pharmacodynamics of pulsatile (No DAC) vs. sustained (DAC) GHRH stimulation
• Body composition endpoints including lean mass accrual and adipose tissue modulation under GH axis stimulation
• Metabolic effects of GH/IGF-1 elevation including insulin sensitivity and glucose homeostasis
• Synergistic GH secretagogue stacking with GHRP-class peptides (e.g., Ipamorelin, GHRP-2, GHRP-6)
• Somatotroph cell biology, GH gene expression, and pituitary responsiveness models
• Sleep-associated GH pulse timing and circadian axis research

Specifications

Reconstitution

CJC-1295 No DAC arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total mg ÷ Volume added (mL) = Concentration (mg/mL)

Example: 2mg vial + 1mL BAC water = 2mg/mL solution

Reconstituted peptide should be stored at 2–8°C and used within 28–30 days.

Protocol Notes

The short half-life of CJC-1295 No DAC (~30 minutes) is a central protocol variable. To maximize GH pulse amplitude while preserving pulsatility, administration timing relative to endogenous GH rhythm is an active area of study — with pre-sleep and post-fast windows being most commonly examined in research models, as these periods coincide with peak somatotroph sensitivity.

Typical research dosing framework:

• Dose range: 100–300mcg per administration
• Frequency: 1–3 times daily; pre-sleep administration most commonly studied for alignment with endogenous GH pulsatility
• Route: Subcutaneous injection; intramuscular also studied
• Combination protocols: Frequently co-administered with Ipamorelin or other GHRP-class peptides to study synergistic amplification of GH pulse amplitude
• Study duration: 4–12 weeks for body composition and IGF-1 endpoint research

Commonly observed effects in research models:

• Acute / transient: Facial flushing, mild headache, transient water retention, tingling or numbness at extremities — most pronounced immediately post-administration and generally short-lived given the brief half-life
• Metabolic: Shifts in fasting glucose and insulin sensitivity at higher doses or sustained protocols; IGF-1 elevation warrants monitoring in long-duration studies
• Other: Injection site irritation; fatigue reported at supraphysiological dose ranges

Research Stacks

CJC-1295 No DAC is commonly paired in research settings with:

• Ipamorelin — CJC-1295 No DAC stimulates GHRH receptors on somatotrophs; Ipamorelin acts on GHSR-1a through a distinct ghrelin-mimetic pathway. Combining them is standard in GH secretagogue research because the two receptor classes synergize to amplify GH pulse amplitude without proportionally elevating cortisol or prolactin.
• GHRP-6 — GHRP-6 is a first-generation ghrelin receptor agonist with established GH-release and appetite-stimulating profiles; it is paired with CJC-1295 No DAC to compare receptor agonist potency under equivalent GHRH stimulation.
• Sermorelin — Both are GHRH analogues with different half-lives and receptor binding kinetics; co-administration studies examine pulse architecture, receptor occupancy, and desensitization dynamics under combined GHRH receptor stimulation.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.